Divestment
Prosensa
Prosensa developed RNA-based therapies for Duchenne muscular dystrophy.
Key Facts
- Sector
Life Sciences
- Country
Netherlands
- Fund
LSP 3, LSP 4
- Entry
2007
- Exit
2015
Responsible Partner
News
Do You Want to Know More?
We are eager to explore how we can achieve great things together.